Impact of Fenugreek Supplementation on Obesity and Hyperglycemia Among Diabetic Adults in Saudi Arabia: A Quasi-Experimental Study
| Registry | NCT07038577 |
|---|---|
| Status | Completed |
| Phase | Not applicable |
| Study type | Interventional; non randomized, parallel, masking: none, treatment |
| Enrollment | 80 (Actual) |
| Sponsor | University of Hail (Other) |
| Conditions | Type 2 Diabetes Mellitus (T2DM), Obesity and Type 2 Diabetes, Hyperglycemia |
| Interventions | Fenugreek Seed Powder (Other) |
| Dates | start 2025-01-01, primary completion 2025-05-01, completion 2025-06-01, first posted 2025-06-26, last updated 2025-06-26 |
| Locations | 1 site in Saudi Arabia |
Related Papers Related Patents Related Grants Related Experts
All trials for Type 2 Diabetes Mellitus (T2DM) All trials for Obesity and Type 2 Diabetes All trials of Fenugreek Seed Powder
The goal of this clinical trial is to learn if Fenugreek seed powder helps lower body weight and blood sugar in adults with type 2 diabetes who are overweight or obese. The main questions it aims to answer are:
Does Fenugreek lower body mass index (BMI)? Does Fenugreek lower fasting blood sugar, random blood sugar, and HbA1c levels? Researchers will compare people who take Fenugreek along with their regular diabetes care to people who receive only standard diabetes care, to see if the Fenugreek supplement adds extra benefits.
Participants will:
Take 10 grams of Fenugreek seed powder twice a day (before breakfast and dinner) for 3 months.
Follow their usual diabetes treatment and a recommended meal plan. Visit the clinic four times during the study to check weight and blood sugar levels.
This study is being done in Hail City, Saudi Arabia.
This clinical trial tested whether Fenugreek seed powder, a natural dietary supplement, could help lower blood sugar and reduce body weight in adults with type 2 diabetes. The study was conducted in Hail City, Saudi Arabia, and involved 80 participants who were either overweight or obese and diagnosed with type 2 diabetes.
Participants were assigned to one of two groups:
The intervention group received 10 grams of Fenugreek seed powder twice daily (before breakfast and dinner) for three months, in addition to their usual diabetes treatment and a standard meal plan.
The control group received only their standard diabetes care and meal plan, without the Fenugreek supplement.
The study used a quasi-experimental pretest-posttest design. Participants' weight (BMI), fasting blood sugar (FBS), random blood sugar (RBS), and HbA1c were measured at the start and monitored throughout the three-month period. Data were collected from local clinics and hospitals that serve people with diabetes in the region.
This study aims to provide evidence on the potential role of Fenugreek as a safe, culturally accepted, and cost-effective supplement that can support diabetes management and reduce obesity-related complications in the Saudi population
| Arm | Type | Interventions | Description |
|---|---|---|---|
| Arm 1: Fenugreek Supplementation | Experimental | Other: Fenugreek Seed Powder | 40 Participants in this group received 10 grams of Fenugreek seed powder twice daily (before breakfast and dinner) for 3 months, in addition to their usual diabetes treatment and a standard meal plan. |
| Arm 2: Standard Care Only | No intervention | 40 Participants in this group continued their usual diabetes treatment and followed a standard meal plan. They did not receive the Fenugreek supplement. |
Sex: All, ages: 18 Years to any
Inclusion Criteria: Adults aged 18 years or older Diagnosed with type 2 diabetes mellitus Body Mass Index (BMI) classified as overweight or obese Receiving standard diabetes treatment (e.g., oral hypoglycemic agents) Able and willing to provide informed consent Residing in Hail City, Saudi Arabia Exclusion Criteria: Diagnosed with type 1 diabetes mellitus Currently using insulin therapy Pregnant or breastfeeding women Known allergy or sensitivity to Fenugreek Diagnosed gastrointestinal diseases or malabsorption conditions Participation in another clinical trial within the past 3 months Any serious medical or psychiatric condition that, in the opinion of the investigators, could interfere with study participation \-
| Facility | City | Country | Status |
|---|---|---|---|
| University of Hail | Ha'il | Saudi Arabia |